Patients with visceral leishmaniasis produce high levels of immunoglobulin, but the specificities of antibodies produced are not well characterized. In an effort to identify leishmania antigens that are specific to Leishmania species or are cross-reactive with other parasitic protozoa, we have cloned and characterized full-length genomic and cDNA clones encoding a Leishmania chagasi acidic ribosomal antigen, LcPO, recognized during human infections. The protein is homologous to the Trypanosoma cruzi and human ribosomal proteins TcPO and HuPO, respectively. Unlike most higher eukaryotes, but similar to TcPO, LcPO has a C-terminal heptapeptide sequence resembling those of the archaebacterial acidic (P-like) proteins. The highly charged C-terminal acidic domain of LcPO contains a serine residue typically found in most eukaryotes but lacking in all T. cruzi P proteins we have characterized thus far. L. chagasi-infected individuals as well as those with T. cruzi infections have antibodies cross-reactive with recombinant LcPO and TcPO as well as HuPO. However, the properties of anti-PO antibodies in T. cruzi and L. chagasi infection sera are quite different. Through the use of synthetic peptides, we showed that while T. cruzi infection anti-TcPO antibodies are exclusively directed against the C-terminal domain of TcPO, L. chagasi infection sera contain antibodies reactive with epitopes other than the C-terminal sequence of LcPO. Thus, anti-LcPO antibodies in L. chagasi infection sera represent the first characterized deviation from the restricted immunodominant C-terminal epitope involved in the generation of anti-PO antibodies following infection or autoimmune diseases.
Leishmlania organisms are intracellular protozoan parasites of macrophages which cause clinical diseases ranging from self-limiting cutaneous lesions to highly destructive mucosal involvement and mild-to-fatal visceral infections. Trypaniosoma cruzi, another intracellular protozoan parasite, is the causative agent of Chagas' disease and is a major cause of chronic heart disease throughout South America. Immunoblotting of parasite antigens as well as immunoscreening of expression libraries, enzyme-linked immunosorbent assays (ELISAs), and immunofluorescence studies, have been used to analyze the humoral immune response to parasite antigens for the identification of specific and cross-reactive antigens of Leishmania chagasi and T cruzi (1, 2, 4-6, 10, 28, 30, 40, 43) . In the case of specific antigens identified through the use of patient infection sera, this is usually interpreted as being species specific. Alternatively, this may simply reflect the biased antibody titers to shared antigens found in sera of individuals with Leishmania or T cruzi infections.
We have been interested in identifying serological epitopes shared by L. chagasi and T cnizi in order to compare their protein sequences, stage regulation, and immunodominant B-cell epitopes. To this end, we screened an L. chagasi The P proteins constitute a family of strongly acidic ribosomal proteins in an environment of mostly basic proteins located within the 60S ribosomal subunit (45, 46) . Subunit depletion and antibody inhibition studies have suggested that the P proteins participate in protein synthesis (23, 34, 36, 42, 47) . In eukaryotes, the P-protein family consists of three members, P0, P1, and P2, which form a pentameric complex in which P1/P2 homodimers are attached to a single P0 protein via their NH,-terminal end (27, 47) . The acidic proteins of eukaryotic and archaebacterial ribosomes, but not the homologous proteins from eubacteria, contain a highly conserved acidic carboxy domain followed by a conserved heptapeptide C-terminal sequence. These conserved C-terminal residues form the basis for the immunological cross-reactivity of the acidic ribosomal proteins both within and across species (14, 16, 33, 39) .
We previously reported the cloning of the T. cruzi homolog, TcPO, following heterologous screening of a T cnrzi trypomastigote cDNA expression library (40) . Of particular interest, although the P proteins are phylogenetically highly conserved, the majority of humans infected with T. cruzi have antibodies to T. cruzi as well as human P proteins. The T. cruzi PO epitope was mapped to the C terminus, a sequence not shared by any other known P protein (40 (4) . Poly(A)+ RNA was purified from total L. chagasi (MHOM/ BR/84/Jonas) promastigote RNA, using standard protocols (35) . A cDNA expression library was constructed with the poly(A)+ RNA, using the ZAP-cDNA unidirectional cloning kit (Stratagene). Construction and screening of the libraries and excision of pBSK(-) phagemid sequences were carried out according to the manufacturer's protocols. A pool of five T. cruzi infection serum samples was adsorbed to remove antiEscherichia coli reactivity (5, 40) and used to screen the L. chagasi genomic expression library. This resulted in the identification of a clone containing a -3.0-kb insert (pLcPO). The 3.0-kb insert of clone pLcPO was used to screen an L. chagasi cDNA library to obtain clones containing the complete coding region of the gene as well as the 5'-spliced leader and 3'-flanking sequences. Overlapping clones were generated from both the coding (pBSK-) and noncoding (pBSK+) strands of the genomic insert by exonuclease III (19) . Singlestrand templates were isolated following infection with VCSM13 helper phage, as recommended by the manufacturer (Stratagene), and sequenced by the dideoxy chain terminator method (37) (40) . Full-length recombinant human P0 (rHuPO) was produced in E. coli, using the pET plasmid vector and a T7 polymerase expression system (Novagen, Madison, Wis.), as described before (39 (44) . Reactivities of the antisera were assessed as previously described (40), using 125I-protein A followed by autoradiography.
ELISA. Microtiter plates (Probind; Falcon) were coated overnight with 250 ng of recombinant antigens or L. chagasi promastigote lysate (1 jig), and the reactivities of patient infection sera were analyzed with protein A-horseradish peroxidase (Zymed) as described previously (32, 40 
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\AAA _~AAAAA followed by a 203-nucleotide 3'-untranslated portion terminating in a stretch of poly(A) residues. The nucleotide sequences of the cDNA insert in the regions of overlap are identical to those of the genomic LcPO clone. Therefore, sequences 5' and 3' of the AUG translation initiation and TAA termination codons represent flanking sequences. The junction of the splice-leader sequence conforms with the splice donor-acceptor site.
Southern blot analysis of LcPO gene sequences. Southern analysis of L. chagasi genomic DNA digested with enzymes which cut both within and outside LcPO revealed, at most, two hybridizing bands when probed with a -1.0-kb internal PstI fragment derived from the genomic pLcPO clone (Fig. 3) . The Pstl digest produced two hybridizing bands of~-1.0 and 2.2 kb. The 1.0-kb hybridizing species is in agreement with the presence of two internal PstI restriction sites separated by 1.0 kb of sequence. With genomic DNA digested with HindIII (which does not cut within LcPO), two hybridizing bands were detected. A virtually identical hybridization pattern was observed when the same blot was probed with the full-length cDNA insert of LcPO (not shown). Taken together, the results of the Southern hybridization argue in favor of the presence of at least two copies of LcPO organized in tandem and contained within a -6.7-kb EcoRV locus (Fig. 3) . Figure 3 also illustrates the cross-species conservation between P0 of L. chagasi and other kinetoplastid protozoa. Homologous sequences were detected in all Leishmania species tested. The hybridizing PstI restriction fragments were identical for all Leishmania species except the L. braziliensis complex. Only under reduced stringency could cross-hybridizing species be detected in the more distantly related parasites T cruzi and T. brucei (not shown).
LcPO is the L. chagasi homolog of the eukaryotic ribosomal acidic phosphoproteins. Figure 4 shows alignment of the [40] ) and human (HuPO [33] ) PO proteins. Gaps (-) have been introduced to maximize the homology. Vertical lines indicate identity, and double dots represent conservative changes. The hydrophobic domain (underlined) is followed by the highly charged segment (+) and a hydrophobic terminus (asterisks). Serine residues (underlined) within the charged (acidic) segment of the leishmania and human sequences are lacking in
deduced primary sequence of L. chagasi P0 with protein sequences of T. cnizi TcPO (40) and HuPO (33) . LcPO has an overall homology of 84% (68.3% identity, 15.5% conservative substitution) with TcPO and 59% (35% identity, 24% conservative substitution) with HuPO. The lengths (322, 323, and 317 amino acids), molecular weights (34,600, 34,900, and 35,300), and isoelectric points (4.9, 4.8, and 5.8) of LcPO, TcPO, and HuPO, respectively, are very similar.
The homology includes a clustering of residues which are evolutionarily conserved in higher eukaryotes: an Ala-rich region adjacent to a highly charged C terminus. This domain is the basis of the serological cross-reactivity among the eukaryotic P proteins (12, 13, 40, 45) . Like other P0 proteins, LcPO has an arginine-lysine-rich region (located at an equivalent position, residues 42 to 70) which is hypothesized to be involved in the binding to rRNA (26) . The C-terminal hydrophobic domain of LcPO is identical to that of TcPO except for a single conservative substitution (alanine to glycine). However, unlike TcPO, the adjacent acidic domain of LcPO is interrupted by a serine residue, a feature characteristic of higher eukaryotic P proteins.
Expression and developmental regulation of LcPO. To estimate the size(s) of LcPO transcripts and determine their expression patterns during parasite development, Northern blots were probed with the full-length cDNA insert of LcPO. Two hybridizing species of -1.4 and 1.3 kb with a relative abundance of 1:4, respectively, were detected in L. chagasi RNA preparations from both the insect stage (promastigote) and the intracellular amastigote forms (Fig. SA) IVT/I P immunoblot analysis of L. chagasi lysates, using rabbit antirLcPO serum. As shown in Fig. SB , the antiserum detected a single protein of -37 kDa in both the promastigote and the amastigote stages. The serum did not cross-react with proteins of sizes expected for the L. chagasi equivalent of P1 and P2 (10 to 14 kDa). The same blot also shows that purified L. chagasi ribosomes (lane rib) contain LcPO (Fig. 5B) . Immunoprecipitations of LcPO from in vitro translations of total L. chagasi promastigote and amastigote RNA ( Fig. 5B ; lanes IVT/IP) were also performed. The sizes of the precipitated bands were indistinguishable from those of cell lysates. Figure 5C shows that rabbit anti-rLcPO antisera cross-reacted with similar PO proteins present in L. donavani, L. tropica, L. braziliensis, L. amazonensis, and T. cruzi but not with human P proteins. In addition, the rabbit anti-LcPO serum bound to the C-terminal peptide (see below) of LcPO but not to a P1/P2 peptide derived from the sequenced T. cruzi genes (39) . The reactivity of the rabbit antiserum on TcPO was not affected by an excess (25 jig) of the P1/P2 peptide, although 1 ,ug of the homologous PO peptide abrogated the reactivity. Therefore, rabbit anti-rLcPO serum may be used to detect P proteins with C-terminal residues similar to those found in LcPO and TcPO.
Reactivity of L. chagasi patient sera with rLcPO. To determine whether L. chagasi-infected individuals make antibodies against LcPO, serum samples from L. chagasi patients were tested on immunoblots of rLcPO and parasite lysate. Figure 6 shows that L. chagasi infection sera contain anti-LcPO antibodies. Pooled sera from uninfected individuals showed no reactivity to LcPO or to L. chagasi lysate. The reactivities of 42 additional L. chagasi infection serum samples on rLcPO were evaluated by ELISA in the absence or presence of an LcPO C-terminal amino acid peptide competitor. We first performed titration experiments with increasing amounts of the peptide competitor, using a range from 1 to 25 jig, and found no significant differences in the residual reactivities of L. chagasi infection sera on rLcPO with 5 to 25 jig of peptide competitor (not shown). Subsequently, all competition studies were performed with 5 jig of LcPO C-terminal peptide. Thirty-eight of the 42 (90.5%) infection serum samples were positive on rLcPO (Fig. 7) , with absorbance values of 0.09 inhibited by the LcP0 peptide. Similar competition studies using a peptide derived from a Leishmania heat shock protein sequence decreased the average absorbance value by only 11%.
We previously demonstrated that the immunological reactivity of sera from T. cruzi-infected individuals on rTcPO was abolished following deletion of the carboxy-terminal six hydrophobic residues of TcPO (40) and that 75% of T. cruzi infection sera had antibodies reactive with the TcPO C-terminal peptide (39) . In the present study, we extended our previous studies to determine the cross-reactivity and epitope analysis of T. cruzi infection sera on rLcPO. All 15 anti-TcPO-positive T. cruzi infection serum samples tested were also positive on rLcPO (Fig. 7) . In addition, the anti-PO antibody titers in T cruzi infection sera were about threefold higher than those found in L. chagasi-infected individuals. In sharp contrast to L. chagasi infection sera, the reactivities of all T. cruzi infection sera with rLcPO were abrogated in the presence of LcPO peptide but not with a similar excess of the heat shock peptide (Fig. 7) . In fact, 1 ,ug of LcPO peptide was as effective as 5 ,ug in abrogating the reactivities of the same T. cruzi infection sera (not shown). These results confirm our previous reports (39, 40) that T. cruzi infection anti-TcPO antibodies are exclusively directed against the C-terminal residues of TcPO. The results also indicate that the conservative (alanine to glycine) as well as additional substitutions in the terminal residues of the LcPO peptide do not affect binding and epitope restriction of T. cruzi patient sera on rLcPO. In this regard, LcP0 peptide is as effective as the TcPO C-terminal peptide in inhibiting the binding of anti-TcPO antibodies in T. cruzi infection sera to rLcPO or rTcPO (not shown). In addition, L. chagasi infection sera reacted strongly to rTcPO (not shown).
Reactivity of L. chagasi patient sera with rHuPO. We previously showed that T. cruzi infection sera with anti-rTcPO antibodies can cross-react with HuPO (39) . In order to determine whether patients positive for anti-LcPO antibodies in L. chagasi-infected individuals cross-reacted with the human P0 homolog, we compared the reactivities of L. chagasi infection sera on rLcPO and rHuPO. All infection sera used were strongly positive on L. chagasi lysate (not shown). Of the 13 patient serum samples that were positive on rLcPO (x = 1.0), 11 samples were also positive on rHuPO, but with absorbance values (x = 0.3) lower than those observed with rLcPO (Fig. 8 ). Only sera with absorbance values that were at least 3 standard deviations greater than the mean absorbance of uninfected controls were scored as positive. All patient sera that were negative on rLcPO were also negative on rHuPO (not shown). (39, 40) , and all five Leishmania species (L. chagasi, L. donovani, L. tropica, L. braziliensis, and L. amazonensis) analyzed in the present study. Therefore, the expression of a ribosomal PO protein with archaebacterial type C-terminal sequences (FGMGA/GLF) different from those found in the PI/P2 proteins (eukaryotic type, MGFGLFD) of the same species appears to be a general feature of the trypanosomatid P-protein family. All five Leishmania species were also found to contain the lower-molecular-weight members (P1/P2) of the P-protein family with C-terminal sequences that are immunologically different from LcPO and TcPO but related to other eukaryotic P proteins (unpublished results).
DISCUSSION
Another feature of the P-protein family of eukaryotes is that their C-terminal acidic domain contains at least one phosphorylation site (usually serine), hence, their designation as phosphoproteins. The serine residue(s) has been shown to represent a phosphorylation site for casein kinase 11 (18, 21, 24) . Phosphorylation of these residues may influence the antigenicity of the P proteins or affect the ribosome function (18, 23, 29, 49) . However, none of the members of the T. cruzi P-protein family we have characterized thus far contain a phosphorylation site within their C-terminal acidic domain (39, 40) . The only exception is a T. cnrzi clone, C-PO (38) , derived from a PCR reaction which encodes the last 78 amino acids of TcPO. Therefore, it was unexpected to find that the acidic C-terminal domains of both the genomic and cDNA sequences of LcPO contain a potential phosphorylation site.
LcPO is transcribed as two mRNA species of -1.3 and -1.4 kb. The variance in lengths of the two LcPO mRNA species does not appear to be due to size differences within their protein coding domains since only one translation product was detected. Therefore, the difference in transcript sizes may reflect transcription products from two different gene copies with variable 5'-and/or 3'-untranslated sequences or the utilization of multiple polyadenylation sites. We showed that the PO gene(s) of L. amazonenis is also transcribed as two mRNA species with sizes identical to those for L. chagasi. In T. crulzi and T. bnrcei, PO is transcribed as a single 1.3-kb mRNA species (40) . The presence of two PO transcripts appears to be a general feature of Leishmania PO. Homologous PO sequences were detected in the genomes of all Leishmania species tested. The hybridizing PstI restriction fragments were identical for all Leishmania species except the L. braziliensis complex, suggesting a high degree of conservation in both the nucleotide sequence and the genomic organization of Leishmania PO genes. Similar sequence conservation was found at the protein level, as demonstrated by immunoblot assays with anti-P antibodies.
During the preparation of this report, the PO gene from another Leishmania species, L. infantulm (LiPO), was cloned and characterized (41 Unlike T cruzi infection sera, the serological reactivity of L. chagasi infection sera with rLcPO was not restricted to the C terminus. Acute visceral leishmaniasis is associated with marked depression of T-cell proliferative responses (9), serum suppressor factors, circulating immune complexes, and marked hypergammaglobulinemia (8, 17) . The increased immunoglobulin levels do not represent only parasite-specific antibodies but rather appear to be a consequence of polyclonal B-cell activation (7, 17, 50) . We found that patient anti-LcPO antibodies also react with rHuPO. This provides evidence for infection-induced, cross-reactive antibodies against a defined antigen shared by the parasite and the host in human visceral leishmaniasis. Similar to the reactivities of L. chagasi infection sera on rLcPO, we expect that the cross-reactive serologic epitope on HuPO is not restricted to the C terminus. Therefore, while patient serological cross-reactivity exists between the P0 proteins of T cruzi and L. chagasi, the selection of anti-PO B-cell epitopes is radically different in patients infected with T. cruzi and L. chagasi.
The target P0 epitope(s) of L. chagasi patient sera represents the first characterized deviation from the restricted immunodominant C-terminal epitope in the generation of anti-PO antibodies either following infection (T cruzi [39, 40] ) or as a spontaneous process in human and mouse systemic lupus erythematosus (14, 16, 20) . Although the use of rLcPO or TcPO cannot alone distinguish between protozoan infection caused by T. cruzi or Leishmania species, these antigens could, in combination with the C-terminal peptide competition assays, be used to distinguish between infection caused by the two different parasites. The differences in the anti-PO epitope selection of TcPO and LcPO most likely reflect the outcome of infection with two different protozoan species causing different diseases rather than differences in the immunogenicity of TcPO and LcPO. Chagas' disease and systemic lupus erythematosus are both chronic diseases characterized by autoimmune pathology, unlike L. chagasi infection. In this regard, it is interesting that the restricted C-terminal epitope selection of TcPO and HuPO in both Chagas' disease and systemic lupus erythematosus and high anti-P-protein antibodies are associated with two unrelated chronic diseases having significant autoimmune components.
